论文部分内容阅读
The purpose of this study was to investigate the changes of protein kinase Cα(PKCα) and cyclin D1 expressions in pulmonary arteries from smokers with normal lung function and smokers with mild to moderate chronic obstructive pulmonary disease(COPD).The peripheral lung tissues were obtained from 10 non-smokers with normal lung function(non-smoker group),14 smokers with normal lung function(smoker group),11 smokers with mild to moderate COPD(COPD group).The morphological changes of pulmonary arteries were observed by HE-staining.The expressions of α-smooth muscle actin(α-SMA),proliferating cell nuclear antigen(PCNA),PKCα and cyclin D1 proteins in pulmonary artery smooth muscle cells(PASMCs) were immunohistochemically determined.The percentages of PCNA-positive cells were taken as the smooth muscle cells proliferation index(PI).The mRNA expressions of PKCα and cyclin D1 in PASMCs were evaluated by real-time fluorescence PCR.Morphometrical analysis showed that the ratio of pulmonary artery wall area to total area(WA%) in smoker group and COPD group was significantly greater than that in non-smoker group(P<0.01).The PASMCs proliferation index in smoker group and COPD group was significantly higher than that in nonsmoker group(P<0.01).The protein levels of PKCα and cyclin D1 in PASMCs were significantly increased in smoker group and COPD group as compared with non-smoker group(P<0.01).The mRNA expressions of PKCα and cyclin D1 in PASMCs were significantly elevated in smoker group and COPD group as compared with non-smoker group(P<0.01).Significant correlations were found between PKCα protein and WA% or PI(P<0.01).Correlations between cyclin D1 protein and WA% or PI also existed(P<0.01).The expression of PKCα was positively correlated with the expression of cyclin D1 at both protein and mRNA levels(P<0.01).In conclusion,increased expressions of PKCα and cyclin D1 might be involved in the pathogenesis of abnormal proliferation of PASMCs in smokers with normal lung function and smokers with mild to moderate COPD.
The purpose of this study was to investigate the changes of protein kinase Cα (PKCα) and cyclin D1 expressions in pulmonary arteries from smokers with normal lung function and smokers with mild to moderate chronic obstructive pulmonary disease (COPD). The peripheral lung tissues were from 10 non-smokers with normal lung function (non-smoker group), 14 smokers with normal lung function (smoker group), 11 smokers with mild to moderate COPD (COPD group) .The morphological changes of pulmonary arteries were observed by HE- staining. The expressions of α-smooth muscle actin (α-SMA), proliferating cell nuclear antigen (PCNA), PKCα and cyclin D1 proteins in pulmonary artery smooth muscle cells (PASMCs) were immunohistochemically determined. percent of PCNA-positive cells were taken as the smooth muscle cells proliferation index (PI). The mRNA expressions of PKCα and cyclin D1 in PASMCs are evaluated by real-time fluorescence PCR. Morphometrical analysis showed that the ratio of pulmonary The plasma wall area to total area (WA%) in smoker group and COPD group was significantly greater than that in non-smoker group (P <0.01). The PASMCs proliferation index in smoker group and COPD group was significantly higher than that in nonsmoker group (P <0.01) .The protein levels of PKCα and cyclin D1 in PASMCs were significantly increased in smoker group and COPD group as compared with non-smoker group (P <0.01) .The mRNA expressions of PKCα and cyclin D1 in PASMCs were significantly elevated in smoker group and COPD group as compared with non-smoker group (P <0.01) .Significant correlations were found between PKCα protein and WA% or PI (P <0.01) .Correlations between cyclin D1 protein and WA% or PI also existed (P <0.01). The expression of PKCα was positively correlated with the expression of cyclin D1 at both protein and mRNA levels (P <0.01). In conclusion, increased expressions of PKCα and cyclin D1 might be involved in the pathogenesis of abnormal proliferation of PASMCs in smokers with normal lun g functionand smokers with mild to moderate COPD